Quantcast
Home > Quotes > VVUS
VVUS

VIVUS, Inc. Common Stock (VVUS) Quote & Summary Data

$3.05
*  
0.16
4.98%
Get VVUS Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading VVUS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VVUS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
10
Today's High / Low
$ 3.229 / $ 3.01
Share Volume
50,244
50 Day Avg. Daily Volume
105,471
Previous Close
$ 3.21
52 Week High / Low
$ 9.88 / $ 3.01
Market Cap
32,421,265
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.07
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.72

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Sep. 11, 2018
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
50,244
50 Day Avg. Daily Volume:
105,471

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.07

Trading Range

The current last sale of $3.05 is 1.33% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.229 $ 9.88
 Low: $ 3.01 $ 3.01

Company Description (as filed with the SEC)

VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs in human health. We have two approved therapies and one product candidate in active clinical development. Qsymia® (phentermine and topiramate extended release) is approved by FDA for chronic weight management. STENDRA® (avanafil) is approved for erectile dysfunction, or ED, by FDA and by the EC under the trade name SPEDRA in the EU. Tacrolimus is in active clinical development for the treatment of patients with pulmonary arterial hypertension, or PAH. Business Strategy Review In 2016, we initiated a business strategy review to maximize long-term stockholder value.  ... More ...  


Risk Grade

Where does VVUS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.20
Open Date:
Nov. 19, 2018
Close Price:
$ 3.05
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x